Monoclonal Antibodies No Better Than Placebo for Early Parkinson Disease
Two studies show lack of benefit in primary or secondary end points with cinpanemab or prasinezumab versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.